CIPO Patents = 1

EPO Patents = 2

Forward Citations = 1

Loading Chart...

4 inventors (with patents filed for the assignee):

Yi-Rang Kim (4 out of 4 patents)

Jin-woo Choi (1 out of 3 patents)

Jin-Woo Choi (1 out of 29 patents)

4. Jin Woo Choi (1 out of 117 patents)

5 patents: Sort by Forward Citations

1. 12514836 - Composition for prevention and treatment of myopathy (2026-01-06),

2. 12064435 - Composition for treatment of muscular disorders (2024-08-20),

3. 11364244 - Compositions for treatment of muscular disorders (2022-06-21),

4. 11364237 - Composition for inhibiting cancer metastasis and treating cancer (2022-06-21),

5. 11219613 - Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof (2022-01-11),

Company Overview

Oncocross Co., Ltd. is a leading biotechnology company specializing in the development and commercialization of innovative oncology therapies. With a focus on precision medicine, our team of experts work tirelessly to advance the field of cancer treatment and improve patient outcomes. Through cutting-edge research and strategic partnerships, Oncocross is committed to delivering game-changing solutions for cancer patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

5 Patents

#672 in Seoul

#1,881 in South Korea

Seoul, South Korea

Oncocross Co., Ltd.

Forward Citations = 1

4 inventors:

Yi-Rang Kim (4 out of 4 patents)

Jin-woo Choi (1 out of 3 patents)

Jin-Woo Choi (1 out of 29 patents)

4. Jin Woo Choi (1 out of 117 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncocross Co., Ltd.. Retrieved from https://idiyas.com/company/oncocross-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]